Opendata, web and dolomites

OvaVAx SIGNED

100% Bacteria free eggs for use in production of human and animal vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OvaVAx project word cloud

Explore the words cloud of the OvaVAx project. It provides you a very rough idea of what is the project "OvaVAx" about.

pharmaceutical    first    superior    considerable    agr    service    company    chicken    investors    2022    vc    serial    industry    providers    skills    protect    transgenics    dr    egg    yields    invested    founders    enterprise    patent    biopharma    ovagen    immunisation    eliminate    yield    biotechnology    services    contamination    ltd    germ    bacterial    free    avian    pandemic    innovation    group    standards    caulfield    contract    eggs    48bn    pull    viral    utilising    vision    91m    supplier    manufacturing    usd    gf    specialises    disruptive    lives    global    moran    innovative    seven       market    spf    good    coo    led    populations    globally    opportunity    cagr    annually    world    industries    size    quality    demands    catherine    worth    health    89bn    entrepreneurs    commercially    pathogen       ogl    protected    12    exceptionally    vaccine    manufacture    whilst    specialist    demand    2021    1bn    leonard    ireland    team    ceo    manufacturers    rapid    external    servicing    benefits    expertise    vaccines    fertilised   

Project "OvaVAx" data sheet

The following table provides information about the project.

Coordinator
OVAGEN GROUP LIMITED 

Organization address
address: CARRENTRILA
city: BALLINA
postcode: F26PC79
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙366˙875 €
 EC max contribution 2˙356˙812 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OVAGEN GROUP LIMITED IE (BALLINA) coordinator 2˙356˙812.00

Map

 Project objective

Disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. Ovagen Group Ltd. (OGL) is an innovation-based biotechnology company, led by serial entrepreneurs, providing specialist contract services to Biopharma, Pharmaceutical and Vaccine industries. OGL specialises in avian Germ-Free (GF) technology and avian transgenics to Good Manufacturing Practice standards. The company’s vision is to be the go-to supplier of superior quality GF eggs to the vaccine industry globally by 2021.

INNOVATION: The founders Dr Leonard Moran CEO and Dr Catherine Caulfield COO together with external VC investors and Enterprise Ireland have invested €12.91M in seven years of R&D, utilising the considerable skills, expertise and experience of our team within this field to develop a unique and novel, patent protected process to enable commercially viable production of the World’s first germ-free (GF) eggs, to eliminate bacterial contamination through eggs for vaccine development and production. This will result in improved quality, production costs and viral yields for vaccine manufacturers leading to cost and availability benefits for health service providers for immunisation programmes to protect the health and lives of populations whilst enabling a rapid response to Global pandemic demands. There is exceptionally strong market pull for our innovative disruptive technology, and the increasing use of vaccines to support global demand for quality eggs estimated CAGR of 8.8% and market value of USD 1.89Bn by 2022.

OPPORTUNITY: Over 1bn fertilised specific pathogen free (SPF) chicken eggs are used annually in vaccine manufacture, servicing a vaccine market size estimated to be worth €48bn by 2021 with an AGR of 8.3%.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More  

Genetta (2019)

Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbing

Read More